Carotuximab
Carotuximab Basic information
- Product Name:
- Carotuximab
- Synonyms:
-
- Carotuximab
- Research Grade Carotuximab (DHD26501)
- Carotuximab (anti-CD105)
- DE-122|||TRC105
- Research Grade Carotuximab
- CAS:
- 1268714-50-6
- MW:
- 0
- Mol File:
- Mol File
Carotuximab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Carotuximab Usage And Synthesis
Uses
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions[1][2].
in vivo
Carotuximab (TRC105; 2 mg/kg; i.v; every 3 days; for 8 weeks) along with Decitabine results in a more durable anti-leukemic effect in acute myeloid leukemia (AML) xenografts. And also enhances reactive oxygen species (ROS) activity[2].
| Animal Model: | Female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; 7-8 weeks) injected with primary AML-0032 cells[2] |
| Dosage: | 2 mg/kg |
| Administration: | i.v; every 3 days; for 8 weeks |
| Result: | Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts. |
References
[1] Katarina Tripska , et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918. DOI:10.3389/fmed.2022.845918
[2] June Baik, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020 Oct 13;6(10):e05242. DOI:10.1016/j.heliyon.2020.e05242
CarotuximabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com